Side-by-side · Research reference

AOD-9604vsPEG-MGF

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED10/47 cited

BAnimal-MechanisticHUMAN-REVIEWED2/69 cited

AOD-9604

HGH 176-191 · β3-AR Lipolytic

250–300 mcgDaily doseHeffernan 2001

Phase 2Evidence levelHeffernan 2001 Ng 2000

~30 minHalf-life

SQ · Abdomen · Daily fasted

PEG-MGF

IGF-1Ec Splice Variant · PEGylated

~2 hrHalf-life (PEG)

~7 minNative MGF t½

IGF-1EcSplice variant

SQ · Research Protocol

01Mechanism of Action

Parameter

AOD-9604

PEG-MGF

Primary target

β3-adrenergic receptor (proposed)Ng 2000

IGF-1 receptor on muscle satellite cells and myocytes

Pathway

β3-AR activation → cAMP → hormone-sensitive lipase activation → triglyceride breakdown to FFA + glycerolNg 2000

IGF-1R → PI3K/Akt → mTOR activation → Satellite cell proliferation & myoblast fusion

Downstream effect

Lipolysis of adipose tissue triglycerides; FFA release for oxidation; minimal IGF-1 / insulin impactHeffernan 2001

Satellite cell activation, muscle fiber repair, localized hypertrophy signaling

Feedback intact?

No GH-axis or IGF-1 feedback

Partially bypassed — does not require hepatic IGF-1 synthesis

Origin

Synthetic modified C-terminal hexadecapeptide fragment of human GH (176-191) with N-terminal Tyr substitutionNg 2000

IGF-1Ec splice variant (exon 4–6) conjugated to polyethylene glycol for extended circulation

Antibody development

—

Unknown — no long-term human immunogenicity data

02Dosage Protocols

Parameter

AOD-9604

PEG-MGF

Standard dose

250–300 mcg / dayHeffernan 2001

Anecdotal SQ range. Phase 2 trial dose 1 mg/day oral.

—

Frequency

Once daily, fasted

Post-training or daily

Timing to match endogenous MGF pulse post-exercise.

Lower / starter dose

150 mcg / day

—

Evidence basis

Phase 2 trials + animal-strongHeffernan 2001 Ng 2000

Animal / mechanistic

Duration

8–12 weeks per cycle

—

Reconstitution

Bacteriostatic water, 1 mL per 2 mg vial → 2 mg/mL

Sterile bacteriostatic water

Lyophilized form; store reconstituted at 2–8 °C.

Timing

Morning fasted preferred (pre-cardio)

Aligns with circadian lipolysis.

Within 30–60 min post-training

Aligns with endogenous MGF window.

Half-life

~30 min plasma

~2 hours (PEGylated)

Native MGF: ~7 min; PEGylation extends circulation.

Research dose range

—

100–200 mcg

Extrapolated from animal models; no validated human protocols.

PEG molecular weight

—

Typically 5–30 kDa

Higher MW = longer t½, greater steric hindrance.

03Metabolic / Fat Loss Evidence

Parameter

AOD-9604

PEG-MGF

Primary target

—

Muscle tissue (satellite cells, myocytes) — not adipose-specific

Indirect metabolic effect

—

IGF-1 signaling may modulate insulin sensitivity and lipid metabolismRen 2015

Mechanism distinct from direct lipolytic peptides.

Body composition

—

Lean mass preservation / hypertrophy focus

Fat loss evidence

—

No direct human or animal RCT data for PEG-MGF-driven fat reduction

04Side Effects & Safety

Parameter

AOD-9604

PEG-MGF

Injection site reaction

Mild erythema

Erythema, induration (common with SQ peptides)

GI symptoms

Rare mild nausea

—

Cardiovascular

Possible mild HR increase via β3-AR (theoretical β1 cross-reactivity)

—

IGF-1 elevation

None — designed to lack GH-axis activityHeffernan 2001

—

Insulin sensitivity

Neutral — no glucose impairmentHeffernan 2001

—

Cancer risk

No GH/IGF-1 axis activity → lower theoretical risk vs HGH

IGF-1 axis stimulation contraindicated in active malignancy

Pregnancy / OB

Avoid

—

Hypoglycemia risk

—

IGF-1 axis activation can lower blood glucose

IGF-1R overstimulation

—

Theoretical risk of aberrant cell proliferation with chronic supraphysiological exposure

Fluid retention

—

Possible with IGF-1 pathway activation (dose-dependent)

PEG accumulation

—

Chronic high-dose PEGylated proteins may accumulate in tissues; clearance slower in renal impairment

Antibody formation

—

PEGylated proteins can elicit anti-PEG antibodies (neutralizing potential unknown)

Human safety data

—

Absent — no published human trials for PEG-MGF

Absolute Contraindications

AOD-9604

·Pregnancy / breastfeeding
·Severe cardiovascular disease (caution with β-receptor agonists)

PEG-MGF

·Active malignancy or history of cancer (IGF-1R proliferative signaling)
·Known hypersensitivity to PEGylated compounds
·Pregnancy / lactation (no reproductive toxicity data)

Relative Contraindications

AOD-9604

·Concurrent β-blocker therapy (theoretical antagonism)
·Pheochromocytoma

PEG-MGF

·Diabetes (monitor glucose closely)
·Renal impairment (PEG clearance reduced)
·Retinopathy (IGF-1 axis effects on vascular proliferation)

05Administration Protocol

Parameter

AOD-9604

PEG-MGF

1. Reconstitution

Add 1 mL bacteriostatic water to 2 mg vial → 2 mg/mL = 200 mcg per 0.1 mL.

Add 1–2 mL bacteriostatic water to lyophilized vial. Swirl gently — do not shake. Solution should be clear to slightly opalescent.

2. Injection site

SQ — abdomen preferred. Rotate sites.

Subcutaneous — abdomen or thigh. Rotate sites to avoid lipodystrophy. Avoid areas with scar tissue or active inflammation.

3. Timing

Morning, fasted, ideally pre-cardio for amplified fat oxidation.

Post-training preferred (within 30–60 min) to align with endogenous MGF expression window. Alternatively, daily morning dose on non-training days.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

Lyophilized: room temperature, light-protected, desiccated. Reconstituted: refrigerate 2–8 °C, use within 14–21 days.

5. Needle

29–31G, 4–8 mm insulin syringe.

29–31G insulin syringe, 8–12 mm length. Pinch skin fold, insert at 45° angle for subcutaneous delivery.

06Stack Synergy

AOD-9604

+ MOTS-c

Moderate

View MOTS-c →

AOD-9604 mobilises FFAs from adipose via β3-AR; MOTS-c upregulates AMPK / PGC-1α / FAO machinery so that mobilised FFAs are efficiently oxidised. The pathways are sequential — supply (AOD) plus demand (MOTS-c) — and produce more durable lipolytic effects than either alone in anecdotal protocols.

AOD-9604: 250–300 mcg SQ · morning fasted (daily)
MOTS-c: 5 mg SQ · 2–3× per week (pre-workout)
Primary benefit: Fat mobilisation + mitochondrial oxidation, no IGF-1 concern

PEG-MGF

+ BPC-157

Moderate

View BPC-157 →

BPC-157 promotes angiogenesis and tendon/ligament repair via VEGF and growth factor modulation, while PEG-MGF targets satellite cell activation and myocyte proliferation. Complementary pathways for comprehensive tissue repair post-injury or intensive training. BPC-157's systemic stability and oral bioavailability contrast with PEG-MGF's localized IGF-1R signaling.

PEG-MGF: 100–200 mcg SQ post-training
BPC-157: 250–500 mcg SQ or oral, twice daily
Duration: 4–6 weeks (injury-dependent)
Primary benefit: Accelerated muscle and connective tissue repair, enhanced recovery

+ TB-500

Strong

View TB-500 →

TB-500 (Thymosin Beta-4 fragment) upregulates actin polymerization, cell migration, and anti-inflammatory pathways, while PEG-MGF drives satellite cell proliferation via IGF-1R/mTOR. Synergistic for muscle regeneration: TB-500 mobilizes progenitor cells, PEG-MGF stimulates their differentiation into myocytes. Both have overlapping but distinct repair cascades.

PEG-MGF: 100–200 mcg SQ post-training
TB-500: 2–5 mg SQ, 2× per week (loading), then weekly
Timing: Stagger injections by 6–12 hours
Primary benefit: Maximal satellite cell recruitment and myogenic differentiation, injury repair